Evidence map›Paper›PMID 21742841›Full record

ArticleThe Journal of infectious diseases2011

IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.

John Scott, Sarah Holte, Thomas Urban, Caitlin Burgess, Erica Coppel, Chia Wang, Larry Corey, John McHutchison, David Goldstein

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Allele-specific PCR for determination of IL28B genotype.Journal of clinical microbiology · 2012
    Article
  8. Genetics of IL28B and HCV--response to infection and treatment.Nature reviews. Gastroenterology & hepatology · 2012
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

John ScottDepartment of Medicine, University of Washington, Seattle, Washington 98104, USA. jdscott@u.washington.edu
Sarah Holte
Thomas Urban
Caitlin Burgess
Erica Coppel
Chia Wang
Larry Corey
John McHutchison
David Goldstein
University of Washington · USDuke University · USVirginia Mason Medical Center · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI MARI M KITAHATA · 1988 to 2026
$104.9M
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCAUL1RR025014 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$51.5M
Mathematical and Experimental Models for HIV DynamicsR01AI055343 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HOLTE, SARAH E · 2003 to 2007
$1.7M
HCV Kinetics and Determinants of RelapseK23RR022206 · NCRR · UNIVERSITY OF WASHINGTON · PI SCOTT, JOHN D · 2006 to 2010
$755k
NCRR NIH HHS K23 RR02206NCRR NIH HHS K23 RR022206NCRR NIH HHS UL1 RR025014NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI055343
6 · The paper itself

Abstract

backgroundMathematical models of hepatitis C virus (HCV) during therapy may elucidate mechanisms of action for antiviral therapy. In genome-wide association studies, IL28B gene polymorphisms are highly predictive of therapeutic clearance of HCV.

methodsWe collected sera from 20 chronically infected HCV participants at 13 points during the first 28 days of therapy. We assessed the presence of the C allele at single-nucleotide polymorphism rs12979860 using the ABI TaqMan allelic discrimination kit. We estimated dynamic parameters from the entire population using the Neumann model for HCV infection. Statistical methods for repeated nonlinear measures compared model parameters by established predictors of response.

resultsThe frequencies of IL28B genotypes were 6 (C/C), 11 (C/T), and 3 (T/T). The mean log decline in HCV RNA from 0 to 48 hours was more rapid among C/C genotype participants compared with C/T or T/T genotype participants (1.4 vs 0.7; P = .07), and from 2 days to 14 days (1.6 vs 0.7; P = .04). In the multivariate model, the C/C genotype predicted a steeper second-phase decline when adjusted for race (P = .01).

conclusionsThe presence of the C/C genotype at IL28B rs12979860 exerts its antiviral effect by increasing the infected hepatocyte death rate. This suggests that an immune-mediated mechanism is responsible.

Indexed as

Polymorphism, Single NucleotideAdultDrug Therapy, CombinationFemaleGenotypeHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2Interferon LambdaInterferonsInterleukinsMaleMiddle AgedModels, TheoreticalPolyethylene GlycolsInterferon-alphaInterferon alpha-2Interferon Lambdainterferon-lambda, humanInterferonsInterleukinspeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirinRNA, Viral

Identifiers

PMID21742841
PMCPMC3132139
OpenAlexW2126171134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.